<?xml version='1.0' encoding='utf-8'?>
<document id="19519341"><sentence text="Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities."><entity charOffset="0-8" id="DDI-PubMed.19519341.s1.e0" text="Caffeine" /></sentence><sentence text="Phenotyping by probe substrates of cytochrome P450 (CYP) and other metabolizing enzymes is widely used to assess the effects of genes, environment and ethnicity on the in vivo metabolism of drugs and environmental chemicals" /><sentence text=" The caffeine metabolic ratio, in urine, plasma or saliva, has been used extensively as an index of CYP1A2, N-acetyltransferase 2 (NAT2), xanthine oxidase (XO) and CYP2A6 enzymatic activities"><entity charOffset="5-13" id="DDI-PubMed.19519341.s3.e0" text="caffeine" /><entity charOffset="138-146" id="DDI-PubMed.19519341.s3.e1" text="xanthine" /><pair ddi="false" e1="DDI-PubMed.19519341.s3.e0" e2="DDI-PubMed.19519341.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19519341.s3.e0" e2="DDI-PubMed.19519341.s3.e1" /></sentence><sentence text=" Phenotyping using plasma or saliva samples to measure the paraxanthine to caffeine (17X/137X) ratio correlates well with many measures of CYP1A2 activity"><entity charOffset="59-71" id="DDI-PubMed.19519341.s4.e0" text="paraxanthine" /><entity charOffset="75-83" id="DDI-PubMed.19519341.s4.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.19519341.s4.e0" e2="DDI-PubMed.19519341.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19519341.s4.e0" e2="DDI-PubMed.19519341.s4.e1" /></sentence><sentence text=" Various urinary metabolic ratios for caffeine phenotyping have been proposed, but shortcomings have been demonstrated for all the proposed urinary metabolic ratios"><entity charOffset="38-46" id="DDI-PubMed.19519341.s5.e0" text="caffeine" /></sentence><sentence text=" Several groups have proposed the urinary ratio of (1-methylxanthine (1X) + 1-methylurate (1U) + 5-acetylamino-6-formylamino-3-methyluracil (AFMU)) to 1, 7-dimethylurate (17U) i"><entity charOffset="51-89" id="DDI-PubMed.19519341.s6.e0" text="(1-methylxanthine (1X) + 1-methylurate" /><entity charOffset="91-139" id="DDI-PubMed.19519341.s6.e1" text="1U) + 5-acetylamino-6-formylamino-3-methyluracil" /><entity charOffset="141-145" id="DDI-PubMed.19519341.s6.e2" text="AFMU" /><entity charOffset="151-169" id="DDI-PubMed.19519341.s6.e3" text="1, 7-dimethylurate" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e0" e2="DDI-PubMed.19519341.s6.e0" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e0" e2="DDI-PubMed.19519341.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e0" e2="DDI-PubMed.19519341.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e0" e2="DDI-PubMed.19519341.s6.e3" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e1" e2="DDI-PubMed.19519341.s6.e1" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e1" e2="DDI-PubMed.19519341.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e1" e2="DDI-PubMed.19519341.s6.e3" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e2" e2="DDI-PubMed.19519341.s6.e2" /><pair ddi="false" e1="DDI-PubMed.19519341.s6.e2" e2="DDI-PubMed.19519341.s6.e3" /></sentence><sentence text="e" /><sentence text=" (1X + 1U + AFMU)/17U as the preferred metabolic ratio for CYP1A2 activity (independent of urine flow rate)"><entity charOffset="12-29" id="DDI-PubMed.19519341.s8.e0" text="AFMU" /></sentence><sentence text=" There is no consensus on the best urinary metabolic ratio for NAT2, XO or CYP2A6 enzymatic activities" /><sentence text=" Caffeine has been used by different groups to evaluate the in vivo activity of CYP1A2, NAT2, XO and CYP2A6 in different populations and the effect of many factors on these activities"><entity charOffset="1-9" id="DDI-PubMed.19519341.s10.e0" text="Caffeine" /></sentence><sentence text=" Caffeine has been also used as a constituent of a &quot;cocktail&quot; to phenotype several enzymes simultaneously"><entity charOffset="1-9" id="DDI-PubMed.19519341.s11.e0" text="Caffeine" /></sentence><sentence text=" In conclusion, phenotyping using caffeine as a probe substrate may still provide useful assessment of CYP1A2, NAT2, XO and CYP2A6 activities in epidemiologic and drug-drug interaction studies despite the limitations that are associated with its use"><entity charOffset="34-42" id="DDI-PubMed.19519341.s12.e0" text="caffeine" /></sentence><sentence text="" /></document>